NeuroMetrix Stock Forecast, Price & News

NeuroMetrix (NASDAQ:NURO) Frequently Asked Questions

What stocks does MarketBeat like better than NeuroMetrix?

Wall Street analysts have given NeuroMetrix a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NeuroMetrix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NeuroMetrix?

NeuroMetrix saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,140,000 shares, an increase of 169.2% from the August 15th total of 423,400 shares. Based on an average daily volume of 9,720,000 shares, the short-interest ratio is currently 0.1 days.
View NeuroMetrix's Short Interest.

When is NeuroMetrix's next earnings date?

NeuroMetrix is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for NeuroMetrix.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) released its quarterly earnings results on Thursday, July, 22nd. The medical device company reported ($0.13) earnings per share (EPS) for the quarter. The medical device company had revenue of $2.21 million for the quarter. NeuroMetrix had a negative net margin of 14.30% and a negative trailing twelve-month return on equity of 19.02%.
View NeuroMetrix's earnings history.

How has NeuroMetrix's stock been impacted by COVID-19?

NeuroMetrix's stock was trading at $1.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NURO shares have increased by 639.0% and is now trading at $10.42.
View which stocks have been most impacted by COVID-19.

When did NeuroMetrix's stock split? How did NeuroMetrix's stock split work?

Shares of NeuroMetrix reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of NeuroMetrix stock prior to the reverse split would have 13 shares after the split.

Who are NeuroMetrix's key executives?

NeuroMetrix's management team includes the following people:

• Shai N. Gozani, Chairman, President & Chief Executive Officer
• Thomas T. Higgins, Chief Financial Officer, Treasurer & Senior VP
• Michael J. MacDonald, Senior VP & General Manager-Diagnostics
• Francis X. McGillin, Chief Commercial Officer & Senior Vice President
• Xuan Kong, Chief Data Scientist

What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?

10 employees have rated NeuroMetrix CEO Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among NeuroMetrix's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NeuroMetrix's key competitors?

Some companies that are related to NeuroMetrix include DarioHealth (DRIO), TELA Bio (TELA), Titan Medical (TMDI), T2 Biosystems (TTOO), Neuronetics (STIM), Liquidia (LQDA), BrainsWay (BWAY), Nemaura Medical (NMRD), Venus Concept (VERO), PolyPid (PYPD), Repro Med Systems (KRMD), AIT Therapeutics (AITB), Lyra Therapeutics (LYRA), Repro-Med Systems (REPR) and Pro-Dex (PDEX).
View all of NURO's competitors.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), salesforce.com (CRM), Nokia (NOK), Ampio Pharmaceuticals (AMPE), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).

What is NeuroMetrix's stock symbol?

NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."

Who are NeuroMetrix's major shareholders?

NeuroMetrix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.66%), Dimensional Fund Advisors LP (0.81%), Citadel Advisors LLC (0.51%) and Virtu Financial LLC (0.22%). Company insiders that own NeuroMetrix stock include Shai Gozani, Thomas T Higgins and Topline Capital Management, Ll.
View institutional ownership trends for NeuroMetrix.

Which institutional investors are buying NeuroMetrix stock?

NURO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Citadel Advisors LLC, Virtu Financial LLC, and Dimensional Fund Advisors LP. Company insiders that have bought NeuroMetrix stock in the last two years include Shai Gozani, and Topline Capital Management, Ll.
View insider buying and selling activity for NeuroMetrix or or view top insider-buying stocks.

How do I buy shares of NeuroMetrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroMetrix's stock price today?

One share of NURO stock can currently be purchased for approximately $10.42.

How much money does NeuroMetrix make?

NeuroMetrix has a market capitalization of $58.65 million and generates $7.38 million in revenue each year.

How many employees does NeuroMetrix have?

NeuroMetrix employs 20 workers across the globe.

When was NeuroMetrix founded?

NeuroMetrix was founded in 1996.

What is NeuroMetrix's official website?

The official website for NeuroMetrix is www.neurometrix.com.

Where are NeuroMetrix's headquarters?

NeuroMetrix is headquartered at 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801.

How can I contact NeuroMetrix?

NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The medical device company can be reached via phone at (781) 890-9989 or via email at [email protected].